Showing results (361-370 of 494) with videos related to
Sort By:
Pageof 50
Future Oncology (London, England)|February 23, 2024
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgeryJohn M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.European Journal of Cancer (Oxford, England : 1990)|April 4, 2025
Conference on challenges in sarcoma (CCS) 2024: Expert opinions on non-evidence-based management aspectsSilvia Hofer, Chantal Pauli, Beata Bode, et al.Nature Medicine|October 16, 2023
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trialJohn M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.European Journal of Cancer (Oxford, England : 1990)|May 27, 2020
The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissectionDaniëlle Verver, A Rekkas, Claus Garbe, et al.Cancer|January 3, 2019
Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working GroupRick L M Haas, Sylvie Bonvalot, Rosalba Miceli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2021
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III StudyYoon-Koo Kang, Suzanne George, Robin L Jones, et al.The Lancet. Oncology|March 28, 2024
Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysisRobert C Stassen, Carolien C H M Maas, Astrid A M van der Veldt, et al.Cell Death & Disease|December 26, 2025
PIM kinase inhibition attenuates pro-tumoral and immunosuppressive functions of macrophages in classic Hodgkin lymphomaMaciej Szydłowski, Ewa Kurtz, Filip Garbicz, et al.Cancers|September 9, 2023
Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or BRAF/MEK Targeted Therapy: Multicenter Real-World ReportJoanna Placzke, Magdalena Rosińska, Paweł Sobczuk, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2025
Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047Evan J Lipson, Sonia Dolfi, Hao Tang, et al.Pageof 50